Decavanadate, a P2X receptor antagonist, and its use to study ligand interactions with P2X7 receptors

European Journal of Pharmacology

Volumn 534, Issue 1-3, 2006, Pages 19-29

  Michel, Anton D ^a,b   Xing, Mengle ^b   Thompson, Kyla M ^b,c   Jones, Clare A ^b,d   Humphrey, Patrick P A ^b,e  

^a GLAXOSMITHKLINE   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c ASTEX PHARMACEUTICALS   (United Kingdom)

^d ASTRAZENECA   (United Kingdom)

^e THERAVANCE INC   (United States)

Author keywords

ATP; Decavanadate; P2X receptor; Vanadate; Vanadium

Indexed keywords

1 [N,O BIS(5 ISOQUINOLINESULFONYL) N METHYL LEVO TYROSYL] 4 PHENYLPIPERAZINE; 2' O (4BENZOYLBENZOYL) ADENOSINE TRIPHOSPHATE; 3' O (4BENZOYLBENZOYL) ADENOSINE TRIPHOSPHATE; ADENOSINE DERIVATIVE; ADENOSINE TRIPHOSPHATE; BRILLIANT BLUE; DECAVANADIC ACID; ETHIDIUM; PIPERAZINE DERIVATIVE; PURINE P2X RECEPTOR; PURINE P2X7 RECEPTOR; PURINERGIC RECEPTOR BLOCKING AGENT; PYRIDOXAL 5 PHOSPHATE; UNCLASSIFIED DRUG; VANADIC ACID; VANADIUM;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL STRAIN HEK293; COMPETITIVE INHIBITION; CONTROLLED STUDY; DATA ANALYSIS; DRUG ANTAGONISM; ELECTROPHYSIOLOGY; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; KINETICS; LIGAND BINDING; NONHUMAN; PRIORITY JOURNAL; PROTEIN INTERACTION; RAT;

CALCIUM SIGNALING; CELL LINE; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; KINETICS; LIGANDS; MEMBRANE POTENTIALS; PYRIDOXAL PHOSPHATE; RECEPTORS, PURINERGIC P2; ROSANILINE DYES; TRANSFECTION; VANADATES;

EID: 33644902898     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2006.01.009     Document Type: Article

References (32)

1. M. Aureliano, and R.M.C. Gândara Decavanadate effects in biological systems J. Inorg. Biochem. 99 2005 979 985
2. A.G. Blakeley, D.A. Brown, T.C. Cunnane, A.M. French, J.C. McGrath, and N.C. Scott Effects of nifedipine on electrical and mechanical responses of rat and guinea pig vas deferens Nature 294 1981 759 761
3. D.W. Boyd, and K. Kustin Vanadium: a versatile biochemical effector with an elusive biological function Adv. Inorg. Biochem. 6 1984 311 365
4. 7 purinoceptor in mouse NTW8 microglial cells Br. J. Pharmacol. 121 1997 1429 1437
5. 7 receptor FEBS Lett. 439 1998 26 30
6. G. Choate, and T.E. Mansour Studies on heart phosphofructokinase. Decavanadate as a potent allosteric inhibitor at alkaline and acidic pH J. Biol. Chem. 254 1979 11457 11462
7. D.C. Crans Aqueous chemistry of labile oxovanadates: relevance to biological studies Comments Inorg. Chem. 16 1994 1 33
8. E. Fenwick, A. Marty, and E. Neher A patch clamp study of bovine chromaffin cells and of their sensitivity to acetylcholine J. Physiol. 331 1982 577 597
9. 2+ release in permeabilized pancreatic acinar cells Cell Calcium 12 1991 735 742
10. A.G. Garcia, A. Jurkiewicz, and N.H. Jurkiewicz Contractile effect of vanadate and other vanadium compounds on the rat vas deferens Eur. J. Pharmacol. 70 1981 17 23
11. C.E. Gargett, and J.S. Wiley The isoquinoline derivative KN-62 a potent antagonist of the P2Z-receptor of human lymphocytes Br. J. Pharmacol. 120 1997 1483 1490
12. O.P. Hamill, A. Marty, E. Neher, B. Sakmann, and F.J. Sigworth Improved patch-clamp techniques for high-resolution current recording from cells and cell-free membrane patches Pflügers Arch. 391 1981 195 198
13. 7 receptors Br. J. Pharmacol. 130 2000 167 173
14. 7 receptors Naunyn-Schmiedeberg's Arch. Pharmacol. 363 2001 639 648
15. S. Hua, G. Inesi, and C. Toyoshima Distinct topologies of mono- and decavanadate binding and photo-oxidative cleavage in the sarcoplasmic reticulum ATPase J. Biol. Chem. 275 2000 30546 30550
16. 7 nucleotide receptor: high selectivity for the human versus rat receptor homologues Mol. Pharmacol. 54 1998 22 32
17. L.H. Jiang, A.B. Mackenzie, R.A. North, and A. Surprenant Brilliant blue G selectively blocks ATP-gated rat P2X(7) receptors Mol. Pharmacol. 58 2000 82 88
18. 2 J. Biol. Chem. 262 1987 8252 8257
19. Y.H. Ko, M. Bianchet, L.M. Amzel, and P.L. Pedersen The chemical mechanism of ATP synthase. Evidence that in the transition state the gamma-phosphate of ATP is near the conserved alanine within the P-loop of the beta-subunit J. Biol. Chem. 272 1997 18875 18881
20. K. Kustin, and I.G. Macara The new biochemistry of vanadium Comments Inorg. Chem. 2 1982 1 22
21. M.A. Le Hir Soluble 5′-nucleotidase in rat kidney. Stimulation by decavanadate Biochem. J. 273 1991 795 798
22. J. Li, G. Elberg, D.C. Crans, and Y. Shechter Evidence for the distinct vanadyl(+4)-dependent activating system for manifesting insulin-like effects Biochemistry 35 1996 8314 8318
23. J.M. Messmore, and R.T. Raines Decavanadate inhibits catalysis by ribonuclease A Arch. Biochem. Biophys. 381 2000 25 30
24. 7 receptor function Naunyn-Schmiedeberg's Arch. Pharmacol. 359 1999 102 109
25. 7 receptor-mediated cellular accumulation of YO-PRO-1 Br. J. Pharmacol. 130 2000 513 520
26. R.A. North, and E.A. Barnard Nucleotide receptors Curr. Opin. Neurobiol. 7 1997 346 357
27. BI. Posner, R. Faure, J.W. Burgess, A.P. Bevan, D. Lachance, G. Zhang-Sun, I.G. Fantus, J.B. Ng, D.A. Hall, and B.S. Lum Peroxovanadium compounds. A new class of potent phosphotyrosine phosphatase inhibitors which are insulin mimetics J. Biol. Chem. 269 1994 4596 4604
28. 7. Cloning and expression of a human cDNA J. Biol. Chem. 272 1997 5482 5486
29. A. Shaver, J.B. Ng, D.A. Hall, and B.I. Posner The chemistry of peroxovanadium compounds relevant to insulin mimesis Mol. Cell. Biochem. 153 1995 5 15
30. S. Varga, P. Csermely, and A. Martonosi The binding of vanadium (V) oligoanions to sarcoplasmic reticulum Eur. J. Biochem. 148 1985 119 126
31. 7 receptor Neuropharmacology 36 1997 1285 1294
32. 4 receptor function J. Neurophysiol. 81 1999 2088 2094